GSK plc
GSK
$38.40
$0.441.16%
NYSE
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 4.13% | 6.26% | 9.08% | 12.16% | 10.31% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.13% | 6.26% | 9.08% | 12.16% | 10.31% |
| Cost of Revenue | 7.14% | 8.40% | 2.62% | 3.09% | -2.04% |
| Gross Profit | 2.99% | 5.44% | 11.77% | 15.97% | 15.79% |
| SG&A Expenses | 21.91% | 21.18% | 24.53% | 9.68% | 11.74% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 66.34% | 68.84% | 19.33% | -42.69% | -113.06% |
| Total Operating Expenses | 17.02% | 18.42% | 15.09% | 7.27% | 4.41% |
| Operating Income | -28.40% | -25.50% | -8.18% | 26.70% | 28.64% |
| Income Before Tax | -23.02% | -41.54% | -53.70% | -19.76% | 6.13% |
| Income Tax Expenses | -22.05% | -29.09% | -41.58% | -2.56% | 19.15% |
| Earnings from Continuing Operations | -23.18% | -43.32% | -55.15% | -22.00% | 4.32% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -81.09% | -2.16% | 23.08% | 27.41% | 12.18% |
| Net Income | -29.53% | -46.81% | -57.52% | -72.22% | -67.46% |
| EBIT | -28.40% | -25.50% | -8.18% | 26.70% | 28.64% |
| EBITDA | -12.34% | -12.54% | -2.82% | 16.05% | 9.50% |
| EPS Basic | -29.99% | -47.12% | -57.78% | -72.43% | -67.67% |
| Normalized Basic EPS | -35.93% | -29.07% | -6.18% | 36.50% | 37.24% |
| EPS Diluted | -29.89% | -47.11% | -57.72% | -72.39% | -67.61% |
| Normalized Diluted EPS | -35.91% | -29.01% | -6.16% | 36.44% | 37.21% |
| Average Basic Shares Outstanding | 0.59% | 0.62% | 0.61% | 0.61% | 0.62% |
| Average Diluted Shares Outstanding | 0.68% | 0.70% | 0.68% | 0.65% | 0.65% |
| Dividend Per Share | 6.66% | 8.08% | 13.06% | 12.98% | 6.28% |
| Payout Ratio | 0.59% | 1.10% | 1.51% | 2.60% | 1.34% |